Keep the evidence in view
Every claim needs context.
A medicine label, a clinical study and a provider page have different jobs. Open a record to see where we used it.
CoreAge Rx: Non-Hormonal ParoxetineChecked 2026-09-27
Provider product page
Checked 2026-09-27. Source content and service terms may change.
Open original source ↗Read it in context
National Institute on Aging: Sleep Problems and MenopauseChecked 2026-09-27
Government patient guidance
Checked 2026-09-27. Source content and service terms may change.
Open original source ↗Read it in context
- CoreAge Rx hot-flash treatment review: what to clarify about day and night relief
- Best hot-flash care options reviewed: compare the visit, the follow-up, and the bill
- Midi hot-flash care review: the appointment, the options, and the next conversation
- Evernow night-sweats care review: sleep goals, access choices, and evidence limits
- Night sweats and sleep: describe the waking, not just the heat
DailyMed: Brisdelle prescribing information, revised April 2025Checked 2026-09-27
FDA-approved labeling
Checked 2026-09-27. Source content and service terms may change.
Open original source ↗Read it in context
- CoreAge Rx hot-flash treatment review: what to clarify about day and night relief
- Best hot-flash care options reviewed: compare the visit, the follow-up, and the bill
- Evernow night-sweats care review: sleep goals, access choices, and evidence limits
- Fewer flashes, milder flashes, easier days: three different treatment goals
- Nonhormonal treatment still needs a medicine-specific safety review
- Read a hot-flash treatment claim in six questions
FDA: Understanding Unapproved Use of Approved DrugsChecked 2026-09-27
FDA guidance
Checked 2026-09-27. Source content and service terms may change.
Open original source ↗Read it in context
Midi: Hot Flashes and Night Sweats TreatmentChecked 2026-09-27
Provider service page
Checked 2026-09-27. Source content and service terms may change.
Open original source ↗Read it in context
Midi: Pricing and InsuranceChecked 2026-09-27
Provider pricing and access terms
Checked 2026-09-27. Source content and service terms may change.
Open original source ↗Read it in context
Midi: Hormone Replacement Therapy and Access TermsChecked 2026-09-27
Provider access terms
Checked 2026-09-27. Source content and service terms may change.
Open original source ↗Read it in context
Evernow: Sleep CareChecked 2026-09-27
Provider service page
Checked 2026-09-27. Source content and service terms may change.
Open original source ↗Read it in context
Evernow: ParoxetineChecked 2026-09-27
Provider treatment page
Checked 2026-09-27. Source content and service terms may change.
Open original source ↗Read it in context
Evernow: Frequently Asked QuestionsChecked 2026-09-27
Provider service and pricing terms
Checked 2026-09-27. Source content and service terms may change.
Open original source ↗Read it in context
DailyMed: Veozah prescribing information, updated February 2026Checked 2026-09-27
FDA-approved labeling
Checked 2026-09-27. Source content and service terms may change.
Open original source ↗Read it in context
- Best hot-flash care options reviewed: compare the visit, the follow-up, and the bill
- Midi hot-flash care review: the appointment, the options, and the next conversation
- Evernow night-sweats care review: sleep goals, access choices, and evidence limits
- Nonhormonal treatment still needs a medicine-specific safety review
Bayer: Lynkuet prescribing information, revised August 2026Checked 2026-09-27
Current manufacturer prescribing information
Checked 2026-09-27. Source content and service terms may change.
Open original source ↗Read it in context
- Best hot-flash care options reviewed: compare the visit, the follow-up, and the bill
- Midi hot-flash care review: the appointment, the options, and the next conversation
- Fewer flashes, milder flashes, easier days: three different treatment goals
- Night sweats and sleep: describe the waking, not just the heat
- Nonhormonal treatment still needs a medicine-specific safety review
- Read a hot-flash treatment claim in six questions
The Menopause Society: 2023 Nonhormone Therapy Position StatementChecked 2026-09-27
Professional society evidence review
Checked 2026-09-27. Source content and service terms may change.
Open original source ↗Read it in context
Evernow: VeozahChecked 2026-09-27
Provider treatment page
Checked 2026-09-27. Source content and service terms may change.
Open original source ↗Read it in context
Evernow: Night SweatsChecked 2026-09-27
Provider symptom education
Checked 2026-09-27. Source content and service terms may change.
Open original source ↗Read it in context
FDA: Lynkuet original-approval drug trials snapshotChecked 2026-09-27
Regulatory trial evidence summary
Checked 2026-09-27. Source content and service terms may change.
Open original source ↗Read it in context
National Institute on Aging: Hot flashes, what can I do?Checked 2026-09-27
NIH patient information
Checked 2026-09-27. Source content and service terms may change.
Open original source ↗Read it in context
NHLBI: Insomnia diagnosis and sleep historyChecked 2026-09-27
NIH patient information
Checked 2026-09-27. Source content and service terms may change.
Open original source ↗Read it in context
NHLBI: Sleep apnea symptomsChecked 2026-09-27
NIH patient information
Checked 2026-09-27. Source content and service terms may change.
Open original source ↗Read it in context
Pinkerton et al.: OASIS 1 and 2 randomized clinical trials, JAMA 2024Checked 2026-09-27
Primary randomized trial abstract
Checked 2026-09-27. Source content and service terms may change.
Open original source ↗Read it in context
Alloy: ParoxetineChecked 2026-09-29
Official 10 mg offer; FDA-approved wording is not independently applied to the advertised preparation, and one-month/three-month supply wording remains unresolved
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
DailyMed: Brisdelle paroxetine capsulesChecked 2026-09-29
Exact oral 7.5 mg capsule label updated April 28, 2025; approved vasomotor indication and warnings remain product-specific, not Alloy 10 mg authentication
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Alloy: terms of useChecked 2026-09-28
Dated platform terms; subscription and shipment cancellation deadlines, first-shipment refund conditions and service-fee exclusions kept separate
Checked 2026-09-28. Source content and service terms may change.
Open original source ↗Read it in context
NHLBI: InsomniaChecked 2026-09-29
Federal sleep-disorder overview, last updated March 24, 2022; diagnostic context, not attribution of a reader’s waking to menopause or a clinic assessment
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
- Alloy review: a hot-flash offer and the separate question of sleep
- Gennev review: separating the hot-flash visit from sleep support
- MyMenopauseRx review: when the heat target and sleep concern diverge
- Stella review: clinical visits, coaching and what a sleep story cannot prove
- Wisp review: when hormone-free dryness care is not hot-flash care
- Joi review: separating a hormonal program from a nonhormonal sleep goal
- FOLX Health review: an inclusive care pathway with separate day and night questions
- Maven Clinic review: a two-visit package and two different symptom goals
Gennev: Symptoms and TreatmentChecked 2026-09-29
Official clinical service and treatment categories; exact nonhormonal medicine selection unconfirmed
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
The Menopause Society: 2023 nonhormone therapy position statementChecked 2026-09-29
PubMed primary professional abstract; vasomotor-symptom evidence categories, dated 2023 and not provider-specific efficacy or later-drug approval
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Gennev: insurance and pricingChecked 2026-09-28
Dated provider fee table and coverage process; doctor/dietitian initial/follow-up costs are separate from pharmacy charges
Checked 2026-09-28. Source content and service terms may change.
Open original source ↗Read it in context
NIA: Sleep and Older AdultsChecked 2026-09-29
Federal older-adult sleep information, reviewed February 6, 2025; multiple causes and daily-function context, not a personal diagnosis or a treatment schedule
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
- Gennev review: separating the hot-flash visit from sleep support
- MyMenopauseRx review: when the heat target and sleep concern diverge
- Pandia Health review: which claim belongs to the nonhormonal menu?
- Stella review: clinical visits, coaching and what a sleep story cannot prove
- Wisp review: when hormone-free dryness care is not hot-flash care
- Joi review: separating a hormonal program from a nonhormonal sleep goal
- FOLX Health review: an inclusive care pathway with separate day and night questions
- Maven Clinic review: a two-visit package and two different symptom goals
MyMenopauseRx: TreatmentsChecked 2026-09-29
Official clinical offer names fezolinetant and other treatment categories; no personal prescription or outcome confirmed
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
DailyMed: Veozah fezolinetant tabletsChecked 2026-09-29
Exact label revised February 2026 with boxed hepatotoxicity warning, required clinical monitoring and product-specific contraindications; not personal clearance
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
MyMenopauseRx: telehealth FAQChecked 2026-09-28
Dated provider visit/pharmacy/refill/coverage/cancellation record; personal prescription, generic identity and clinical decisions remain unverified
Checked 2026-09-28. Source content and service terms may change.
Open original source ↗Read it in context
Pandia Health: Menopause careChecked 2026-09-29
Official current clinical/pharmacy menu includes paroxetine and Veozah; pharmacy stock, selected medicine and malformed three-month billed amount unresolved
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Stella US: Menopause careChecked 2026-09-29
US clinical offer, age/access and payment information; nonhormonal category and coaching do not identify a particular medicine
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Wisp: Menopause Consult OnlineChecked 2026-09-29
Official clinical offer and separately billed local-pharmacy medicines; exact systemic nonhormonal medicine offer unconfirmed
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Wisp: Non-Hormonal Vaginal MoisturizerChecked 2026-09-29
Official specific local-dryness offer and latex-condom caution; marketing does not establish vasomotor efficacy or a complete formulation
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Wisp: terms of useChecked 2026-09-28
Dated platform transaction terms; prescription renewal review, 48-hour cancellation and discretionary product remedies; not individual legal advice
Checked 2026-09-28. Source content and service terms may change.
Open original source ↗Read it in context
Joi + Blokes: Clinical care overviewChecked 2026-09-29
Official menopause clinical service and coaching roles; no specific nonhormonal vasomotor prescription confirmed
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Joi + Blokes: Hormone replacement therapyChecked 2026-09-29
Hormonal program prices and quarterly commitments; not a confirmed nonhormonal medicine menu or quote
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
DailyMed: Lynkuet elinzanetant capsulesChecked 2026-09-29
Exact current label revised August 2026; product-specific warnings and use, not a claim any reviewed clinic supplies it
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
FOLX: Perimenopause and menopause supportChecked 2026-09-29
Official LGBTQIA+ clinical service description with nonhormonal medication category; specific product and indication unconfirmed
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
FDA: Understanding unapproved use of approved drugsChecked 2026-09-29
Federal explanation distinguishing an approved medicine from an unapproved use; not a personal recommendation
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
FOLX: What can a clinician help with?Checked 2026-09-29
Official clinical service, published visit charges and appointment cancellation terms; not personal availability
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
FOLX: What is a membership?Checked 2026-09-29
Official membership explainer dated August 2023 as currently accessible; monthly versus annual billed amounts, services extra
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
FOLX: Membership cancellation policyChecked 2026-09-29
Official membership notice, annual account control timing, no membership refunds and remaining bills; separate appointment cancellation terms
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Maven: Hormone Care EssentialsChecked 2026-09-29
Direct clinical offer with stated nonhormonal medicine families and one-time care package; individual eligibility, selected drug and refund outcome unconfirmed
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Maven: Terms of UseChecked 2026-09-29
Official platform terms updated September 23, 2026; independent practitioner roles and enterprise distinctions, not a complete selected Hormone Care refund agreement
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Veozah (fezolinetant) US prescribing informationChecked 2026-09-29
Exact official DailyMed label. Revised February 2026; boxed hepatotoxicity warning; same-day official HTML record reviewed with original timestamp
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Lynkuet (elinzanetant) US prescribing informationChecked 2026-09-29
Exact official DailyMed label. Text revised August 2026; page metadata says updated June 16, 2026; same-day official HTML record reviewed with original timestamp
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Brisdelle (paroxetine) US prescribing informationChecked 2026-09-29
Exact official DailyMed label. Revised April 2025; exact 7.5 mg capsule, not general paroxetine tablets; same-day official HTML record reviewed with original timestamp
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Allara: care program and service FAQsChecked 2026-09-29
Actual menopause care scope; state and program distinctions
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Allara help center: program costsChecked 2026-09-29
Official linked support record; self-pay, insurance and excluded charges
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Allara: how care worksChecked 2026-09-29
Broader weight-care page with different Complete Care and nutrition prices; selected quote unresolved
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Allara: telehealth informed consentChecked 2026-09-29
Initial monthly commitment and ongoing subscription terms
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Allara: terms and conditionsChecked 2026-09-29
Subscription cancellation and discretionary refund conditions; no legal advice
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Hello Alpha: menopause treatmentChecked 2026-09-29
Clinical service page; local estrogen and systemic nonhormonal categories need separation
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Hello Alpha: membershipChecked 2026-09-29
Published monthly plan and visit units; separate prescription charges
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Hello Alpha: terms of useChecked 2026-09-29
Commercial terms; automatic renewal, separate refill cancellation and refund limits
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Myla Health: consultation servicesChecked 2026-09-29
UK private clinical service; NHS prescribing remains separate
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Myla Health: prices effective April 1, 2026Checked 2026-09-29
UK visit and prescription-administration fees, excluding actual medicine
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Myla Health: patient FAQsChecked 2026-09-29
UK location, billing, cancellation and investigation responsibility conditions
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Newson Clinic: consultationsChecked 2026-09-29
UK hormone and nonhormonal consultation scope; exact drug unconfirmed
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Newson Clinic: current services and displayed feesChecked 2026-09-29
Commercial service and fee record; no independent efficacy claim
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Mass General Brigham: Menopause and Midlife ClinicChecked 2026-09-29
Regional clinical program and appointment contacts; no exact drug menu verified
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Penn Medicine: menopause and postmenopause careChecked 2026-09-29
Clinical service; current new center focus on cancer survivors and previvors
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Penn Medicine: contact and schedulingChecked 2026-09-29
Appointment contact hours; no personal availability or price established
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
FDA: unapproved uses of approved drugsChecked 2026-09-29
Regulator explanation; product and indication scope
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
NIA: sleep problems and menopauseChecked 2026-09-29
Patient guidance, content reviewed September 30, 2021; multiple contributors and distinct insomnia assessment
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
- Veozah review: trial evidence, safety and complaints
- Lynkuet review: sleep benefits, satisfaction and complaints
- Brisdelle review: fewer attributed awakenings is a specific sleep finding
- Allara hot-flash care review: separate the daytime goal from the nighttime concern
- Hello Alpha hot-flash review: an online visit is not a blanket sleep promise
- Myla Health hot-flash review: bring both the daytime and overnight account
- Newson Clinic hot-flash review: which appointment fits the question being asked?
- Mass General Brigham hot-flash review: place the sleep concern within the care pathway
- Penn Medicine hot-flash review: distinguish the general service from the new center
Paroxetine 7.5 mg: pooled phase 3 sleep analysisChecked 2026-09-29
Primary trial analysis, predefined secondary self-reported endpoints; placebo comparison and Noven funding; historical regulatory/discontinuation statements not current guidance
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Fezolinetant: DAYLIGHT phase 3b randomized trialChecked 2026-09-29
Primary placebo-controlled 24-week study; secondary sleep P values not multiplicity controlled; Astellas funding; current label controls safety
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Elinzanetant: OASIS 1 and 2 randomized trialsChecked 2026-09-29
Primary placebo-controlled trials; sleep T-score secondary endpoint at week 12, crossover thereafter; current label controls later safety warnings
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
JAMA: OASIS 1 and 2 sponsor and funder roleChecked 2026-09-29
Original primary publisher disclosure; Bayer sponsorship and study, analysis, manuscript and submission roles
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Duke Health — MenopauseChecked 2026-09-29
Official menopause clinical service description. Treatment categories and symptom scope do not establish a selected medicine, individual sleep diagnosis, personal outcome or total cost. Page states internal medical review December 7, 2021; access date is separate.
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Cleveland Clinic — Menopause TreatmentChecked 2026-09-29
Official menopause clinical service description. Treatment categories and symptom scope do not establish a selected medicine, individual sleep diagnosis, personal outcome or total cost.
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Mayo Clinic — Menopause and Women’s Sexual Health ClinicChecked 2026-09-29
Official menopause clinical service description. Treatment categories and symptom scope do not establish a selected medicine, individual sleep diagnosis, personal outcome or total cost. Rochester, Minnesota service; page dated February 3, 2026.
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Johns Hopkins Medicine — Menopause ClinicChecked 2026-09-29
Official menopause clinical service description. Treatment categories and symptom scope do not establish a selected medicine, individual sleep diagnosis, personal outcome or total cost.
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Mount Sinai — MenopauseChecked 2026-09-29
Official menopause clinical service description. Treatment categories and symptom scope do not establish a selected medicine, individual sleep diagnosis, personal outcome or total cost. Historical SWAN study-year wording is not adopted as a current timeline or medicine trial.
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Northwestern Medicine — Program for MenopauseChecked 2026-09-29
Official menopause clinical service description. Treatment categories and symptom scope do not establish a selected medicine, individual sleep diagnosis, personal outcome or total cost.
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
UCLA Health — Comprehensive Menopause Program Clinical ServicesChecked 2026-09-29
Official menopause clinical service description. Treatment categories and symptom scope do not establish a selected medicine, individual sleep diagnosis, personal outcome or total cost.
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
Stanford Health Care — Menopause TreatmentsChecked 2026-09-29
Official menopause clinical service description. Treatment categories and symptom scope do not establish a selected medicine, individual sleep diagnosis, personal outcome or total cost.
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
University of Utah Health — Midlife Women’s Health and Menopause ProgramChecked 2026-09-29
Official menopause clinical service description. Treatment categories and symptom scope do not establish a selected medicine, individual sleep diagnosis, personal outcome or total cost.
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
UCLA Health — Comprehensive Menopause Program Patient InformationChecked 2026-09-29
Official UCLA appointment instructions: questionnaire preparation, as-needed follow-up and annual health assessment. The annual review is not a drug-specific monitoring interval.
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
University of Utah Health — What to Expect at Your Midlife AppointmentChecked 2026-09-29
Official Utah appointment guide, internally reviewed February 2025: preparation and 40–60-minute first visit. Symptom ranking is not a diagnosis, eligibility score or medicine protocol.
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
National Institute on Aging — Sleep Problems and Menopause: What Can I Do?Checked 2026-09-29
Federal patient explanation, internally reviewed September 30, 2021. Multiple contributors to poor sleep, uncertain waking/hot-flash sequence and trained-professional insomnia therapy; no personal diagnostic or bedtime regimen.
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
- Duke Health hot-flash care review: start with what interrupts the day
- Cleveland Clinic review: hot flashes, night sweats and appointment questions
- Johns Hopkins hot-flash care review: use the referral to clarify the unresolved problem
- Mount Sinai hot-flash care review: research about symptom patterns is not a personal forecast
- Northwestern menopause care review: hot flashes and insomnia are both listed, not equated
- UCLA Health hot-flash care review: keep the sleep question visible in a broad assessment
- Stanford hot-flash care review: a medicine menu and a separate sleep assessment
- University of Utah hot-flash care review: rank the concern before comparing options
Pinkerton and colleagues — Low-dose paroxetine improves sleep in women with vasomotor symptoms associated with menopauseChecked 2026-09-29
Primary 2015 report of predefined secondary sleep outcomes in two placebo-controlled trials of a specific paroxetine mesylate capsule. Self-reported outcomes; sleep-onset and other scales did not show uniform benefit. Industry funded; not an insomnia indication, current safety clearance or clinic outcome.
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
NIH Discover Women’s Health — InsomniaChecked 2026-09-29
Federal research overview of insomnia symptoms, assessment and treatment. Used for distinctions between sleep concerns; does not confirm a provider service or a particular medicine’s insomnia approval.
Checked 2026-09-29. Source content and service terms may change.
Open original source ↗Read it in context
- Duke Health hot-flash care review: start with what interrupts the day
- Cleveland Clinic review: hot flashes, night sweats and appointment questions
- Johns Hopkins hot-flash care review: use the referral to clarify the unresolved problem
- Mount Sinai hot-flash care review: research about symptom patterns is not a personal forecast
- Northwestern menopause care review: hot flashes and insomnia are both listed, not equated
- UCLA Health hot-flash care review: keep the sleep question visible in a broad assessment
DailyMed — BRISDELLE paroxetine capsule, Legacy Pharma USA, Inc.Checked 2026-10-21
Exact capsule prescribing information revised April 2025. Menopausal vasomotor indication and current safety information remain separate from older secondary sleep outcomes and from a clinic formulary.
Checked 2026-10-21. Source content and service terms may change.
Open original source ↗Read it in context
DailyMed — VEOZAH fezolinetant tablet, Astellas Pharma US, Inc.Checked 2026-10-21
Complete current prescribing information revised February 2026, including boxed hepatotoxicity warning, all three contraindications, liver-assessment duties and patient warning response. Vasomotor indication is not an insomnia indication; no personal laboratory calendar or eligibility decision.
Checked 2026-10-21. Source content and service terms may change.
Open original source ↗Read it in context
CoreAge Rx: shipping reference and service detailsChecked 2026-10-12
Homepage shipping reference; customer service and payment details supplied for this review, without a checkout or timed support test
Checked 2026-10-12. Source content and service terms may change.
Open original source ↗Read it in context
Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials.Checked 2026-10-21
Indexed primary study abstract
Checked 2026-10-21. Source content and service terms may change.
Open original source ↗Read it in context
Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause.Checked 2026-10-21
Indexed primary study abstract and full research article
Checked 2026-10-21. Source content and service terms may change.
Open original source ↗Read it in context
Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.Checked 2026-10-21
Indexed primary study abstract
Checked 2026-10-21. Source content and service terms may change.
Open original source ↗Read it in context
Lynkuet prescribing information: November checkChecked 2026-11-08
Official label revised August 2026; freshly accessed, with earlier records retained.
Checked 2026-11-08. Source content and service terms may change.
Open original source ↗Read it in context
OASIS 1 registry resultsChecked 2026-11-08
Sponsor-submitted trial record; questionnaire findings do not measure customer satisfaction.
Checked 2026-11-08. Source content and service terms may change.
Open original source ↗Read it in context
OASIS 2 registry resultsChecked 2026-11-08
Sponsor-submitted trial record; read alongside the separately dated publication record.
Checked 2026-11-08. Source content and service terms may change.
Open original source ↗Read it in context
Cleveland Clinic menopause service: November checkChecked 2026-11-08
Official appointment information; no booking, insurance or personal eligibility tested.
Checked 2026-11-08. Source content and service terms may change.
Open original source ↗Read it in context
Veozah prescribing information: November checkChecked 2026-11-08
Official label revised February 2026; freshly accessed, with earlier records retained.
Checked 2026-11-08. Source content and service terms may change.
Open original source ↗Read it in context
DAYLIGHT full article: November checkChecked 2026-11-08
Full primary article accessed through Europe PMC for this update.
Checked 2026-11-08. Source content and service terms may change.
Open original source ↗